Tirzepatide, a dual GLP-1 and GIP receptor agonist, has shown powerful results for weight management, but gastrointestinal effects including irritable bowel syndrome (IBS) symptoms occur in a meaningful portion of users
The combination supports gut barrier integrity and microbiome health, contributing to long-term digestive and metabolic benefits.*
Health Canada noted that a causal link had not been established between the products and the reported adverse effects
Hers offers weight care within a broad multi-condition platform
Substantially less pronounced than the robust orexigenic responses driven by GHRP-6 and GHRP-2 through hypothalamic NPY/AgRP activation
However, they have some problems, such as side effects, high costs, and the need to make changes to your lifestyle